Pharma tech firms announce global MES partnership
Zenith Technologies and Werum IT Solutions to help improve pharma companies' production performance.
Zenith Technologies and Werum IT Solutions have formed a global partnership to support pharmaceutical companies with the implementation of manufacturing execution system (MES) technology to improve production performance.
The collaboration brings together Werum IT Solution’s MES PAS-X software, which is designed to increase efficiency, improve productivity and meet regulatory requirements during pharmaceutical manufacturing, with Zenith Technologies’ ability to integrate systems and provide on-the-ground automation technical support. The PAS-X software is used by the majority of the world’s top 30 pharmaceutical and biotech companies but also by many regional and mid-sized manufacturers.
The partnership, which was signed at Werum’s headquarters in Lüneburg, Germany, makes Zenith Technologies an Endorsed Service Partner of Werum IT Solutions in both the US and Europe. Zenith Technologies will support Werum customers during all MES implementation phases, delivering comprehensive support and consultancy services that complement Werum’s manufacturing IT solutions.
“We are delighted to partner with Zenith Technologies,” says Torsten Isenberg, Senior Director Services at Werum IT Solutions GmbH. “As an Endorsed Service Partner, Zenith Technologies has the knowledge and experience required to be part of our PAS-X service partner program. Our main objective is to ensure a high level of support for our customers through reliable, experienced and certified partners.”
Brendan O’ Regan, chairman and founder, Zenith Technologies, adds: “Given our combined expertise in automation and the similarities in our customer base, the collaboration represents a strategic move for both companies. By combining Werum’s MES technology with our technical implementation experience, we can provide customers with a high quality of service, training and local level support, helping them to remain both compliant and competitive. We are continually investing in training and working together with Werum and other solution providers to ensure we stay ahead with the latest technology.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance